Cargando…
Oxathiazinane derivatives display both antineoplastic and antibacterial activity: a structure activity study
PURPOSE: The Oxathiazinane substance class is characterized by a high diversity of chemical structures yet to be fully investigated. Our research group recently proved that the 1.4.5-oxathiazine-4.4-dioxide, known as substance GP-2250, possesses antineoplastic properties as shown on pancreatic carci...
Autores principales: | Majchrzak-Stiller, B., Buchholz, M., Peters, I., Strotmann, J., Möhrke, J., Zelichowski, L., Oehlke, L., Quensel, C., Fein, D., Höhn, P., Müller, T., Uhl, W., Braumann, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374762/ https://www.ncbi.nlm.nih.gov/pubmed/37171614 http://dx.doi.org/10.1007/s00432-023-04799-8 |
Ejemplares similares
-
Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma—A 3-D In Vitro Study
por: Baron, Claudia, et al.
Publicado: (2022) -
GP‐2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP‐Kinase and impairs the NF‐kB pathway in pancreatic cancer cells
por: Majchrzak‐Stiller, Britta, et al.
Publicado: (2023) -
New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo
por: Buchholz, Marie, et al.
Publicado: (2022) -
The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results
por: Gambichler, Thilo, et al.
Publicado: (2023) -
Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo
por: Buchholz, M., et al.
Publicado: (2017)